By using our website you accept our cookies policy.Find out more

Horizon 2020: Innovative Medicines Initiative 2 Call 10

Registration is closed
Funding details
Registration opens
04 Jan 2017, 12:00
Registration closes
28 Mar 2017, 12:00
28 Mar 2017, 12:00
Horizon 2020

Call identifier: H2020-JTI-IMI2-2016-10-TWO-STAGE

NOTE two-stage deadlines: First stage closing date 28 March 2017, second stage closing date 14 September 2017.


The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).

Expected Results

The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI’s first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.

This call for proposals includes the following topics. Click on the topic to link directly to the Participant Portal.

For full details of the calls for proposals, please click the Register button below to link directly to the Participant Portal.